Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are currently covering the company ...

TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario ...

The renowned medical device company has a market capitalization of $2.31 billion. Tandem Diabetes projects a growth rate of 28.6% for 2025 earnings compared with 18.7% for the S&P 500. TNDM delivered ...

In the near and long term, the company aims to strategically expand the adoption of the insulin pump by type 1 diabetes patients across all its market. The Tandem Diabetes team is actively working ...

Park Avenue Securities LLC boosted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 34.5% in the 4th ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...

Bernstein analyst Lee Hambright raised the firm’s price target on Tandem Diabetes (TNDM ... pulsed field ablation, insulin pumps, and new AI-enabled functionality across medtech segments ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, ...

Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in ...